Completed

Oligomeric HIV-1 gp160MN/LAI-2 Vaccine Alone or With Live Recombinant ALVAC-HIV (vCP205) for HIV Prevention in Seronegative Adults

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

gp160 MN/LAI-2

+ ALVAC-HIV MN120TMG (vCP205)

Biological
Who is being recruted

Blood-Borne Infections+11

+ Urogenital Diseases

+ Genital Diseases

From 18 to 55 Years
+14 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Prevention Study

Phase 1
Interventional
Study Start: April 1998
See protocol details

Summary

Principal SponsorWalter Reed Army Institute of Research (WRAIR)
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

Study start date: April 1, 1998

Actual date on which the first participant was enrolled.

This study consists of 2 parts: Part A: Dose-escalation protocol using oligomeric gp160MN/LAI-2. Part B: Placebo-controlled, randomized, double-blind (within arm) study of vCP205 priming with gp160MN/LAI-2 boosting. Volunteers are followed for at least 1 year.

NCT00004579
Principal SponsorWalter Reed Army Institute of Research (WRAIR)
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Prevention Study

Prevention studies aim to stop a disease from developing. They often involve people at risk and test things like vaccines, lifestyle changes, or preventive medications.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 55 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Blood-Borne InfectionsUrogenital DiseasesGenital DiseasesCommunicable DiseasesImmunologic Deficiency SyndromesImmune System DiseasesInfectionsRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesVirus DiseasesSexually Transmitted Diseases, ViralLentivirus InfectionsHIV Infections

Criteria

6 inclusion criteria required to participate
Agree to practice sexual abstinence or use birth control
Are HIV-negative
Are a resident of the United States of America
Are available for at least 1 year
Show More Criteria
8 exclusion criteria prevent from participating
Are allergic to eggs or other vaccines
Are an employee at a participating site and have access to study information
Are pregnant or breast-feeding
Are taking certain medications
Show More Criteria

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Walter Reed Army Institute of Research

Rockville, United StatesOpen Walter Reed Army Institute of Research in Google Maps
CompletedOne Study Center